Connect with us


Should You Worry About This Threat to Moderna’s Vaccine? – Motley Fool

The question is whether it will hurt future revenue — or not.



Article feature image

Moderna’s (NASDAQ:MRNA) success story is all about its coronavirus vaccine. The product generated a whopping $1.7 billion in revenue in the first quarter and brought the company its first ever quarter of profitability. This is big — especially considering Moderna didn’t have any commercialized products until regulators authorized the vaccine in late December.
Investors are hoping this is just the beginning of Moderna’s coronavirus vaccine revenue growth. It should be. Experts say the virus is here…

Click here to view the original article.

Continue Reading

You might also like ...

Article feature image
FAA group urges move to gender-neutral terms, no more ‘airman’ or ‘cockpit’ – New York Post
Article feature image
Dow Jones Futures: Stock Market Rally Gains Momentum On Biden Infrastructure Deal; Nike Stock Races To New High – Investor’s Business Daily
Article feature image
Infrastructure deal produced a ‘jailbreak’ moment on Wall Street, Jim Cramer says – CNBC